

Shield Therapeutics plc
("Shield" or the "Group")

Appointment of Joint Broker

London, UK, 8 May 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru[®], announces the appointment of finnCap Ltd as its joint broker with immediate effect.

- Ends -

For further information please contact:

Shield Therapeutics plc

Carl Sterritt, Chief Executive Officer
Tim Watts, Chief Financial Officer

www.shieldtherapeutics.com

+44 (0)20 71868500

Nominated Advisor and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 74188900

Joint Broker

finnCap Ltd

Geoff Nash /Matt Radley/ Alice Lane

+44 (0)20 72200500

Financial PR & IR Advisor

Walbrook PR

Paul McManus / Helen Cresswell

+44 (0)20 79338780 or shield@walbrookpr.com

+44 (0)7980 541893 / +44 (0)7841 917679

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru[®], for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru[®] is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.